Innovar en es it fr

Innovar Brand names, Innovar Analogs

Innovar Brand Names Mixture

  • No information avaliable

Innovar Chemical_Formula


Innovar RX_link

Innovar fda sheet

Innovar msds (material safety sheet)

Innovar MSDS

Innovar Synthesis Reference

No information avaliable

Innovar Molecular Weight

166.24 g/mol

Innovar Melting Point

No information avaliable

Innovar H2O Solubility

Appreciable as liquid hydrochloride salt

Innovar State


Innovar LogP


Innovar Dosage Forms

Liquid for injection

Innovar Indication

For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.

Innovar Pharmacology

Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Muscarinic receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the muscarinic receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetyl choline allow the remaining receptors to function more efficiently.

Innovar Absorption

Rapidly absorbed.

Innovar side effects and Toxicity

With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).

Innovar Patient Information

No information avaliable

Innovar Organisms Affected

Humans and other mammals